Compare Cassava Sciences Inc (FLNA) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Phillips 66 — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Phillips 66 trades at $224.36 (market cap $86.00B). The key difference: Phillips 66 is far larger — about 1801× Cassava Sciences Inc's market cap, and Phillips 66 pays a 2.36% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PSX | |
|---|---|---|
Market Cap | $47.75M | $86.00B |
Sector | Health | Energy |
52-Week High | $4.64 | $224.36 |
52-Week Low | $0.87 | $120.04 |
Enterprise Value | -$34.93M | $102.46B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Phillips 66 (PSX) trades at $203.91, down 0.78% on the day, with a bearish technical signal but strong fundamental tailwinds from refining margins. Recent Q2 2026 earnings of $9.41 per share beat estimates, driven by high utilization and robust cash flow. The stock has support near $201 and resistance at $206, with a consensus price target of $221.92 suggesting upside potential.
Outlook is positive due to sustained refining profitability and debt reduction, but risks include volatile crude prices and geopolitical tensions. Analysts are predominantly bullish (57% buy ratings), though technical indicators warn of near-term pressure. Investors should weigh strong fundamentals against sector cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
